



March 23, 2020  
For Immediate  
Release

*Biopharmaceutical Research Company praises the DEA and DOJ for issuing the proposed rule to regulate the federally legal cultivation of cannabis.*

**Biopharmaceutical Research Company** (“BRC”) lauded the federal government’s efforts to implement regulations to satisfy the requirements of the Controlled Substances Act and several international narcotics treaties. BRC is ready and able to exceed the requirements for the federally compliant cultivation of cannabis for scientific and medical research as laid out by the DEA in its Federal Register posting on March 23, 2020.

BRC is registered with the Drug Enforcement Administration (DEA) to study cannabis products and registered to bulk manufacture cannabis for pharmaceutical development nearly four years ago.

Former Navy SEAL and the Founder and CEO of BRC, George Hodgin, remarked, “We have anxiously awaited the release of this rule and its content for nearly four years. This is a monumental step forward for Veterans, patients groups and advocates that have long fought for the scientific community to have access to clean, consistent and compliant cannabis for research. The men and women of the DEA and DOJ have worked hard to craft a regulatory framework for the future of federal cannabis policy in the United States. We are thrilled to work within that framework to deliver value and therapies to patients around the world. We built BRC around federal compliance and standard pharmaceutical quality practices and it is encouraging that the DEA and the DOJ have recognized the importance of compliance and quality. The importance of this announcement cannot be underestimated.”

### **About Biopharmaceutical Research Company**

BRC currently holds a DEA Registration and is working with the DEA for approval to manufacture clean, consistent and compliant cannabis for federally approved researchers around the world.

###